Skip to main content
. 2021 Dec 14;16:3347–3362. doi: 10.2147/COPD.S340113

Figure 6.

Figure 6

Specific CpG sites in the Nrf2 promoter are hypermethylated in human COPD lung and CSE-treated HBE cells. Hypermethylation of the Nrf2 promoter in COPD tissues, primary bronchial epithelial cells and HBE cells. (A and B) Bisulfite sequencing analysis (BSP) was performed to determine the CpG methylation status of the Nrf2 promoter (−632 to −1 bp) in peripheral lung tissues. Methylated (●) and unmethylated (○) CpGs are indicated. The first two CpG sites (CpG_1, −632 bp and CpG_2, −580 bp) were hypermethylated in peripheral lung tissues. (C and D) The first two sites were methylated in lung tissues from COPD patients as assessed by pyrosequencing analysis. (E and F) Only the first CpG site exhibited methylation in primary bronchial epithelial cells based on pyrosequencing analysis. (G and H) HBE cells were treated with 0% or 5% CSE for 72 h. Only the first site exhibited methylation in 5% CSE-treated HBE cells based on pyrosequencing analysis. All data are shown as means ± S.E.M. *P<0.05; **P < 0.01.